Since the concordance level in KRAS mutational status between tumor tissue and ctDNA is high (∼92%) [77], the detection of KRAS mutations in ctDNA has been proposed as a rapid and minimally-invasive alternative method to tissue biopsy for predicting the response to anti-EGFR treatment [78]. This evidence concerns the gene KRAS and neoplasm.